Epigenetic upregulation of Schlafen11 renders WNT- and SHH- activated medulloblastomas sensitive to cisplatin.
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-oncology"
DOI: 10.1093/neuonc/noac243
Abstract: BACKGROUND Intensive chemotherapeutic regimens with craniospinal irradiation have greatly improved survival in medulloblastoma patients. However, survival markedly differs among molecular subgroups and their biomarkers are unknown. Through unbiased screening, we found Schlafen family member 11… read more here.
Keywords: medulloblastoma; slfn11 expression; cisplatin; shh activated ... See more keywords
Prognostic Impact of Schlafen 11 in Bladder Cancer Patients Treated with Platinum-based Chemotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer science"
DOI: 10.1111/cas.15207
Abstract: The utility of Schlafen 11 (SLFN11) expression as a predictive biomarker for platinum-based chemotherapy has been established for cancers from different histologies. However, the therapeutic relevance of SLFN11 in bladder cancer (BC) is unknown. Here,… read more here.
Keywords: based chemotherapy; slfn11 expression; platinum based; slfn11 ... See more keywords
Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.978875
Abstract: Recently, Schlafen family member 11 (SLFN11) has been reported to increase the sensitivity of cancer cells to DNA-damaging agents, including platinum derivatives; thus, SLFN11 may be a predictive biomarker for platinum-based chemoradiotherapy (CRT). In this… read more here.
Keywords: slfn11; slfn11 expression; schlafen family; platinum based ... See more keywords